About: Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
Creator	Liu, Lei Wang, Zhaoqin Zhang, Guoliang Gao, Hong Zhang, Juanjuan Bi, Jing Di, Wencheng He, Xing Li, Zigang Meng, Juan Ou, Min Xiao, Guohui Yang, Rongqing
source	Medline; PMC
abstract	The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension.
has issue date	2020-03-31(xsd:dateTime)
bibo:doi	10.1080/22221751.2020.1746200
bibo:pmid	32228222
has license	cc-by
sha1sum (hex)	6ec40e4904ee8252a0a88bb5e4879225329adcff
schema:url	https://doi.org/10.1080/22221751.2020.1746200
resource representing a document's title	Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
has PubMed Central identifier	PMC7170368
has PubMed identifier	32228222
schema:publication	Emerg Microbes Infect
resource representing a document's body	covid:6ec40e4904ee8252a0a88bb5e4879225329adcff#body_text
is schema:about of	named entity 'addition' named entity 'ENROLLED' named entity 'DISEASES' named entity 'DYSFUNCTION' named entity 'RAS' named entity 'DISEASE' named entity 'viral load' named entity 'global health' named entity 'ACE2' named entity 'cardiovascular diseases' named entity 'ACE2' named entity 'comorbidities' named entity 'ARBs' named entity 'ACEI' named entity 'hypertension' named entity 'viral load' named entity 'blood pressure' named entity 'inflammatory cytokine' named entity 'inflammatory responses' named entity 'COVID' named entity 'coronavirus infection' named entity 'ACEI' named entity 'hypertension' named entity 'ACEI' named entity 'Ang II' named entity 'ACEI' named entity 'SARS' named entity 'T2D' named entity 'viruses' named entity 'Angiotensin II' named entity 'signs and symptoms' named entity 'RAS' named entity 'COVID-19' named entity 'Renin-angiotensin system' named entity 'CD8 T cell' named entity 'ARBs' named entity 'CD3' named entity 'peripheral blood' named entity 'ACEI' named entity 'COVID' named entity 'world economy' named entity 'AT1R' named entity 'antihypertensive treatment' named entity 'ACEI' named entity 'COVID' named entity 'informed consent' named entity 'statistically significant' named entity 'antihypertensive drug' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'neutrophil' named entity 'AT1R' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'antihypertensive drugs' named entity 'ACEI' named entity 'ACEI' named entity 'ACEI' named entity 'ACEIs' named entity 'viral load' named entity 'acute lung injury' named entity 'Count data' named entity 'SPSS' named entity 'pathogenesis' named entity 'ORCID' named entity 'CHD' named entity 'ACEI' named entity 'AT1R' named entity 'SARS-CoV-2' named entity 'β-blockers'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software